Cord blood stem cell therapy - Gamida Cell

Drug Profile

Cord blood stem cell therapy - Gamida Cell

Alternative Names: CordIn; NiCord; UC MSC; Umbilical cord blood stem cell therapy - Gamida Cell; Umbilical cord mesenchymal stem cells

Latest Information Update: 23 Dec 2016

Price : $50

At a glance

  • Originator Gamida-Cell
  • Class Antirheumatics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Acute myeloid leukaemia; Acute lymphoblastic leukaemia; Myelodysplastic syndromes
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Haematological malignancies
  • Phase I/II Haemoglobinopathies; Sickle cell anaemia; Thalassaemia
  • Preclinical Autoimmune disorders; Metabolic disorders

Most Recent Events

  • 01 Nov 2016 Phase-III clinical trials in Haematological malignancies (In adolescents, In adults) in Netherlands, Spain, USA (IV) (NCT02730299)
  • 27 Jul 2016 Gamida Cell initiates enrolment in a phase I/II trial for Sickle cell anaemia in USA
  • 27 Jul 2016 Gamida Cell plans a phase I/II trial for Aplastic anaemia in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top